Desenvolvemento e aplicación de aneis de corte oxidativo selectivo con múltiples grupos sulfhidrilo

Desenvolvemento e aplicación de aneis de corte oxidativo selectivo con múltiples grupos sulfhidrilo

Research background and challenges

Selective ring closure of multiple sulfhydryl compounds is a key step in the synthesis of sulfur-containing heterocyclic compounds, but the traditional method has the following problems:

  • Multiple sulfhydryl reaction activities are similar, making it difficult to achieve selective control. Many side reactions, complex products, and difficult to isolate and purify. The reaction conditions are harsh and the scope of application is limited. We have successfully developed a new selective oxidative ring-closing technology, which completely solves the above problems and achieves efficient and precise ring-closing reaction.

Technical breakthroughs

  • Innovative oxidation system: The first alkyne amide-based oxidation system is proposed, which significantly improves the selectivity.
  • Unique reaction design: through a variety of different positions of the sulfhydryl substrate, the precise ring closure of multiple sulfhydryl substrates is achieved.

Technical Advantages

  • High selectivity: precise identification of target sites among multiple sulfhydryl substrates to achieve single product generation.
  • High efficiency: the reaction conditions are mild, and the reaction yield is significantly improved.
  • Universality: applicable to the synthesis of various sulfur-containing heterocyclic compounds.

Application Fields

  • Drug synthesis: construction of sulfur-containing heterocyclic drug molecules (e.g., thiophene, benzothiophene, dithiopyrrolidine, etc.).
  • Functional materials: preparation of sulfur-containing polymer materials (e.g. self-repairing materials, conductive polymers, etc.).
  • Chemical biology: study the formation and function of protein disulfide bonds.

Avatar de administrador

Xiaoxia Chen

Nova droga R&D Técnico Experiencia básica: Descubrimento do obxectivo, relación estrutura-actividade (SAR) análise, conxugados peptídico-fármaco (PDC), e o desenvolvemento de péptidos anti-envellecemento e metabólicos.

Perfil: Xiaoxia Chen liderou o descubrimento precoz e a investigación preclínica de varios fármacos peptídicos metabólicos e dirixidos a tumores. Non só é experta no cribado de alto rendemento de bibliotecas de péptidos, senón que tamén é experta na utilización de bioloxía computacional asistida por IA para o deseño de secuencias peptídicas de novo.. Actualmente, está liderando un equipo dedicado á investigación e desenvolvemento en profundidade de agonistas multifuncionais de próxima xeración (como dual- ou péptidos reductores de graxa de triple obxectivo) e péptidos altamente activos de reparación de tecidos.

Feito comprobado & Pautas editoriais
Revisado por: Expertos na materia
Comparte este artigo
Casa Busca Whatsapp Servizos Produto